Back to search

Ireland· IE-PA-EU/1/09/538/004

Afinitor 10 mg Tablet

A everolimus product containing everolimus, registered in Ireland by Novartis Europharm Limited. The same ATC class is registered in 3 of our 19 countries.

ATC L01XE10

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedAfinitor 10 mg TabletATCL01XE10REGISTER NO.IE-PA-EU/1/09/538/004PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Everolimus is registered in 3 of 19 countries.

Countries holding a registration under ATC L01XE10 (everolimus), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 2 of them publish a price we can compare per daily dose

Everolimus · ATC L01XE10

3 / 19 countries

  • Ireland
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Everolimus
Manufacturer
Novartis Europharm Limited
Country
Ireland (IE)
ATC code
L01XE10
ATC class
Everolimus
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/09/538/004

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

430 interactions on record for everolimus.

Graded by severity as the source publishes them — 165 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Everolimus · interactions on record

430 records

  • 165 severe
  • 255 moderate
  • 8 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Everolimus in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All everolimus products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Certican, Everolimus Ethypharm
  • Belgium · Certican, Everolimus Eg
  • Bulgaria · Еверолимус Крка, Еверолимус Майлан
  • Cyprus · Certican, Everolimus Pharmazac
  • Czechia · Certican, Everolimus Accord
  • Germany · Certican, Everofin
  • Denmark · Certican, Everolimus Krka
  • Estonia · Certican, Everolimus Krka
  • Spain · Certican, Everolimus Accord
  • Finland · Aderolio, Certican
  • France · Certican, Everolimus Arrow
  • United Kingdom (Northern Ireland) · Aderolio, Aderolio 250 Mcg Tablets
  • Greece · Certican, Everolimus Faran
  • Croatia · Certican, Everolimus Krka
  • Hungary · Certican, Everolimus Accord
  • Iceland · Afinitor, Certican
  • Italy · Certican, Everolimus Accord
  • Liechtenstein · Afinitor, Votubia
  • Lithuania · Certican, Everolimus Norameda
  • Luxembourg · Certican, Everolimus Eg
  • Latvia · Certican, Everolimus Norameda
  • Malta · Certican, Everolimus Ascend
  • Netherlands · Certican, Certican Dispers
  • Norway · Afinitor, Certican
  • Poland · Aderolio, Certican
  • Portugal · Certican, Everolimus Ethypharm
  • Romania · Certican, Everolimus Accord
  • Sweden · Certican, Everolimus Avansor
  • Slovenia · Certican, Everolimus Krka
  • Slovakia · Certican, Everolimus Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f50720ee-c17a-4570-9bd4-2059c047b535
GET /v1/drugs/f50720ee-c17a-4570-9bd4-2059c047b535?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01XE",
    "L01XE10"
  ],
  "strength": null,
  "pa_number": "EU/1/09/538/004",
  "substances": [
    "Everolimus"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "03/08/2009",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about everolimus.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.